Evidence record · ER-KPV-GUT-023
Does KPV reduce gut inflammation in people?
KPV reduces gut inflammation or improves gut disease in people
KPV has no dependable human exposure or outcome evidence for reducing gut inflammation. Cell systems and mouse colitis models support a research hypothesis, not a clinical treatment conclusion. In its 2026 review, FDA reported that it had identified no clinical studies or human exposure data for KPV drug products.
Claim boundary
What this verdict covers
The claim requires patient-important outcomes in a named human gastrointestinal condition. Cell signalling and induced mouse colitis are preclinical layers, not human treatment evidence.
- Compound
- KPV
- Population
- People with inflammatory gastrointestinal conditions
- Outcome
- Symptoms, endoscopic disease or inflammatory outcomes
- Record ID
- ER-KPV-GUT-023
Evidence synthesis
What the research can support
KPV has shown anti-inflammatory activity in intestinal cell systems and animal models. FDA’s 2026 compounding assessment reported no identified clinical studies or human exposure data, leaving the claim below the first-in-human evidence layer.
Why the confidence is very low
Human pharmacology, benefit, adverse-event frequency and product identity are unknown. Free-base and acetate materials should not be assumed to be equivalent.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-KPV-GUT-023 addresses one bounded question: Does KPV reduce gut inflammation in people?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 4 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Preclinical only, the verdict is Insufficient and confidence is Very low. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| FDA 2026 KPV compounding review | FDA reported no identified clinical studies or human exposure data and assessed substance identity. | It is not a test of an individual UK product. | 10 August 2026 |
| KPV in experimental colitis | The study reported activity in mouse colitis models. | A mouse model does not establish benefit in people. | 10 August 2026 |
| KPV intestinal transport research | Cell and animal work examined transport and inflammatory pathways. | It is not a human clinical trial. | 10 August 2026 |
| KPV in cultured human keratinocytes | The study reported a laboratory anti-inflammatory signal in human-derived cells. | Human cells in culture are not human exposure. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on KPV for this claim?
The verdict is insufficient for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
KPV has shown anti-inflammatory activity in intestinal cell systems and animal models. FDA’s 2026 compounding assessment reported no identified clinical studies or human exposure data, leaving the claim below the first-in-human evidence layer. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is KPV authorised in the UK for this use?
No UK marketing authorisation was identified for this use or for a medicine sold under this peptide name. The MHRA products database should be checked for the exact product and presentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Athletes should check the current WADA Prohibited List and obtain sport-specific advice. An experimental or non-approved peptide may fall within the S0 category even when it is not named individually. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What could change this verdict?
A regulated first-in-human programme followed by controlled trials in a defined condition using objective disease measures and patient-reported outcomes. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation